161 related articles for article (PubMed ID: 21095444)
1. Can the early elimination of calcineurin inhibitors result in clinical benefits?
Weir MR
Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
[TBL] [Abstract][Full Text] [Related]
2. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
3. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
4. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
Sommerer C; Giese T; Meuer S; Zeier M
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
[TBL] [Abstract][Full Text] [Related]
5. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
Danger R; Giral M; Soulillou JP; Brouard S
Curr Opin Organ Transplant; 2008 Dec; 13(6):609-13. PubMed ID: 19060551
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
Engelen MA; Amler S; Welp H; Vahlhaus C; Gunia S; Sindermann JR; Rothenburger M; Stypmann J
Transplantation; 2011 May; 91(10):1159-65. PubMed ID: 21478817
[TBL] [Abstract][Full Text] [Related]
7. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
8. Out with the old, in with the new: immunosuppression minimization in children.
Sarwal MM
Curr Opin Organ Transplant; 2008 Oct; 13(5):513-21. PubMed ID: 19060535
[TBL] [Abstract][Full Text] [Related]
9. Steroid-free maintenance immunosuppression and ABO-incompatible transplantation.
Gloor J; Matas AJ
Transplantation; 2010 Mar; 89(6):648-9. PubMed ID: 20010327
[No Abstract] [Full Text] [Related]
10. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
11. [Low-toxicity immunosuppressive therapy in renal transplant].
Scolari F; La Manna G; Comai G; Cappuccilli ML; Todeschini P; Ciavatti A; Persici E; Feliciangeli G; Stefoni S
G Ital Nefrol; 2007; 24 Suppl 38():44-8. PubMed ID: 17922447
[TBL] [Abstract][Full Text] [Related]
12. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
13. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
15. [The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
Schena FP; Maiorano A; Rossini M
G Ital Nefrol; 2008; 25 Suppl 44():S11-4. PubMed ID: 19048580
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
Kuypers DR
Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
[No Abstract] [Full Text] [Related]
17. CNIs: immediate benefits but storing problems for the future?
Kiuchi T
Transplantation; 2008 Oct; 86(8):1026-7. PubMed ID: 18946338
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitors in liver transplantation: to be or not to be.
CastroagudÃn JF; Molina E; Varo E
Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
[TBL] [Abstract][Full Text] [Related]
19. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
